Hantaviruses as Zoonotic Pathogens in Germany

Detlev H. Krüger, Rainer G. Ulrich, Jörg Hofmann

SUMMARY

Background: Hantavirus disease is a zoonosis of increasing clinical importance. A new incidence peak was reached in Germany in 2012, with more than 2800 reported cases. These viruses are transmitted from small mammals to human beings. The disease begins with high fever and non-pathognomonic manifestations that can end in shock and organ failure.

Methods: This article is based on a selective literature search, on the authors’ experiences at the National Referral Laboratory for Hantavirus Infections (Nationales Konsiliarlaboratorium für Hantaviren), and on published recommendations from Germany and abroad.

Results: Two hantavirus species cause clinically relevant infections in Germany. Puumala virus, which is transmitted by bank voles, causes large outbreaks of disease every 2 to 3 years in the southwestern and western regions of Germany and in the Bavarian Forest. Dobrava-Belgrad virus, transmitted by striped field mice, causes infections in the north and east of the country. Serological tests are available for primary and confirmatory diagnosis; moreover, viral nucleic acids can be amplified in the early phase of illness and compared with the viral nucleic acids from the reservoir hosts of the corresponding type of infection. Infections with American types of hantavirus have ca. 35% case fatality, and hantaviruses from southeastern Europe and Asia are also highly pathogenic; in contrast, the febrile illnesses caused by hantaviruses in Germany are usually relatively mild.

Conclusion: When persons living in high-risk areas present with fever of unknown origin or with renal dysfunction of unknown origin, physicians should consider the possibility of a hantavirus infection and should initiate the appropriate diagnostic evaluation.

Cite this as:
A abrupt fever
● Headache, stomach ache, aching flanks and/or back
● In many cases, nausea/vomiting
● Chills
● Conjunctivitis
● Often transient visual disturbances.

In this first stage, patients are often treated with analgesics and antipyretics, which are later mistakenly blamed for the later-occurring renal failure that is actually due to the infection. The different clinical stages can be identified more or less clearly depending on the severity of the disease. The 3- to 4-day febrile stage is followed by a hypotensive stage during which other hemostatic disturbances may also occur, which may manifest as microhemorrhage (including skin petechiae and conjunctival bleeding). Next comes the oliguric stage (Box 1). This critical stage is followed by polyuria and convalescence. Clinical symptoms and parameters on which a suspected diagnosis of hantavirus disease may be based in Germany are summarized in Box 2.

BOX 1

Characteristic symptoms and findings in the acute stages of hantavirus disease

● Stage 1
High fever (3–4 days); non-specific “flu-like” symptoms such as headache, myalgia, chills, and conjunctivitis; severe, often colic-like flank pain, abdominal pain, nausea and vomiting

● Stage 2
Hypotension; other hemostatic disorders; conjunctival bleeding and skin petechiae

● Stage 3
Renal failure; marked proteinuria and microhematuria; creatinemia; thrombocytopenia, leukocytosis, uremia and oligo-/anuria; extrarenal manifestations (e.g., CNS involvement or severe pulmonary symptoms) may be seen

● Further stages
Polyuria
Convalescence

● Course of disease due to hantaviruses occurring in America
High fever, cough, hypoxia, shock, pulmonary edema with tachypnea, dyspnea, and non-productive cough, interstitial pneumonia with mononuclear infiltrates, adult respiratory distress syndrome (ARDS)

(From 3, 4, 7, 9, 10, 11)

BOX 2

Criteria for a suspected diagnosis of hantavirus disease

● Acute onset of illness with fever >38.5 °C
● Back pain/headache/abdominal pain
● Proteinuria and/or hematuria
● Raised serum creatinine
● Thrombocytopenia
● Oliguria and subsequent polyuria

If at least four of the above criteria are present, a suspected diagnosis of hantavirus disease (hemorrhagic fever with renal syndrome) should be made.

(From 33)

Life-threatening developments can occur in the form of shock during the hypotensive stage or the occurrence of renal and/or cardiopulmonary failure. The frequency with which these life-threatening processes develop correlates with the degree of virulence of the various hantaviruses and the case fatality they trigger. In severe cases, the patient requires dialysis or extracorporeal oxygenation. Externally visible bleeding is typical of infection by the hantaviruses found in Asia, and for this reason the World Health Organization (WHO) has suggested the name “hemorrhagic fever with renal syndrome” (HFRS). In hantavirus-induced cardiopulmonary syndrome (HCPS), which is caused by hantaviruses circulating in America, the striking features are hypoxia and bilateral interstitial pulmonary infiltrates that start 2 days after disease onset (3, 7). Since, however, organ damage is not always restricted to the main target organ, and HFRS in Europe is associated with much less external hemorrhage than in Asia, the general term “hantavirus disease” is coming into increasing use (12). The Robert Koch Institute, by the way, has been using this term for years.

Renal retention values start to rise during the febrile stage, reaching their highest during the oliguric stage. The rise in serum creatinine concentration, which is often dramatic (>620 μmol/L) (13), is combined with proteinuria and microhematuria in the reduced amount of urine. Paraclinically, thrombocytopenia and, often, leukocytosis are found. In addition to the renal and/or pulmonary manifestations, in some cases other organ involvement is seen, for example concomitant hepatitis, myocarditis, thyroiditis, panhypopituitarism, or cerebral manifestations. Patients who survive hantavirus disease usually recover without sequelae, but renal hypertension is under discussion as a possible late consequence (14). The severity of hantavirus disease depends very much on which type of the virus has infected the patient (Table).
The pathogenesis of hantavirus disease is marked by vasodilation and disturbances of the capillary endothelial barrier, resulting in extravasation of blood and inflammatory processes in the internal organs, such as the kidneys. At the same time, changes occur in the coagulability of the blood. The strength of the specific CD8-T-cell response and the synthesis of inflammatory cytokines appears to be correlated to the severity of disease (4). In addition, there have been first observations of an interaction between pathogenic hantaviruses and platelet precursor cells and with the platelets themselves (15). So far, attempts to turn these first results about the immune pathogenesis into a therapeutic strategy have failed.

**Pathogens and their natural hosts**

Hantaviruses are negative-sense RNA viruses with three genome segments and a capsid. They form a genus to themselves within the Bunyavirus family. Unlike representatives of other Bunyavirus genera (for example, the pathogens that cause Crimean–Congo hemorrhagic fever and sandfly fever in the region around the Mediterranean Sea), they are transmitted, not by arthropod bites, but usually by aerosols. According to their genetic and serological differences as well as the animal reservoirs they colonize, the hantaviruses can be subdivided into various species, including the Puumala virus and Dobrava–Belgrade virus species found in Germany (Table).

Human beings are “accidental hosts” for hantaviruses and are infected via virus-containing secretions (feces, urine, saliva) of the host animals. Maintenance of viral infectivity outside the host organism depends on a variety of factors such as temperature, humidity, and presence of protective protein, and under optimal conditions is estimated at several weeks (16). Horizontal transmission of the pathogen from person to person has not been described in Europe.

A number of different hantavirus species are in circulation in Germany (Table). The one that most commonly causes disease in humans is the Puumala virus. Since no case of infection of a human by the Saaremaa genotype has yet been verified, it is not regarded as a human pathogen (19).

<table>
<thead>
<tr>
<th>Disease</th>
<th>Virus species</th>
<th>Reservoir host</th>
<th>Distribution of the virus and of the disease</th>
<th>Mortality (approx.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HFRS</td>
<td>Puumala virus (PUUV)*1</td>
<td>Bank vole (Myodes glareolus)</td>
<td>Europe</td>
<td>&lt;1%</td>
</tr>
<tr>
<td></td>
<td>Dobrava-Belgrade virus (DOBV)*2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kurkino (DOBV-Aa)*2</td>
<td>Striped field mouse (Apodemus agrarius)</td>
<td>Central and Eastern Europe</td>
<td>0.3–0.9%</td>
</tr>
<tr>
<td></td>
<td>Dobrava (DOBV-Af)</td>
<td>Yellow-necked mouse (Apodemus flavicollis)</td>
<td>Balkans</td>
<td>10–12%</td>
</tr>
<tr>
<td></td>
<td>Sochi (DOBV-Ap)</td>
<td>Black Sea field mouse (Apodemus ponticus)</td>
<td>Russia (Crimea)</td>
<td>&gt;6%</td>
</tr>
<tr>
<td>Tula virus (TULV)*1</td>
<td>Common vole (Microtus arvalis)</td>
<td>Europe *2</td>
<td>?</td>
<td></td>
</tr>
<tr>
<td>Hantaan virus (HTNV)</td>
<td>Striped field mouse (Apodemus agrarius)</td>
<td>Asia</td>
<td>10–12%</td>
<td></td>
</tr>
<tr>
<td>Seoul virus (SEOV)</td>
<td>Rats (Rattus rattus, Rattus norvegicus)</td>
<td>Asia and possibly worldwide</td>
<td>1–2%</td>
<td></td>
</tr>
<tr>
<td>HCPS</td>
<td>Sin Nombre virus (SNV)</td>
<td>Deer mouse (Peromyscus maniculatus)</td>
<td>North America</td>
<td>35%</td>
</tr>
<tr>
<td></td>
<td>Andes virus (ANDV)</td>
<td>Long-tailed pygmy rice rat (Oligoryzomys longicaudatus)</td>
<td>South America</td>
<td>35%</td>
</tr>
</tbody>
</table>

*1 Hantaviruses in circulation in Germany. The large majority of clinical cases are due to PUUV infection; in the north-eastern parts of the country, DOBV infections occur.
*2 The fourth genotype of the Dobrava–Belgrade virus demonstrated in Europe is the Saaremaa genotype, which is sometimes regarded as a separate species of the virus. Since no case of infection of a human by the Saaremaa genotype has yet been verified, it is not regarded as a human pathogen (19).
*3 There is only one clinical report of a case of TULV infection.
that are hosted by different *Apodemus* species and cause disease of very varying degrees of severity (19). In Germany, infection of humans by this virus has so far only been described in the north and north-east of the country. This is because the distribution of the striped field mouse is restricted to those parts of Germany. In addition, a third hantavirus, the Tula virus, is present in the common vole (*Microtus arvalis*) and related cricetine rodents. It is not yet known how important the Tula virus is as a pathogen in humans; so far only one case of disease has been associated with infection by this virus (20). Finally, two hantaviruses (Seewis virus and Asikkala virus) have been demonstrated in shrews in Germany, but their pathogenicity for humans is unclear at present (21, 22).

Looking at the number of hantavirus infections reported annually since 2001, marked variations can be seen (*Figure 1*). The average number of reported cases each year is around 230, but much higher numbers were reported in 2007, 2010, and 2012 (www3.rki.de/SurvStat). These hantavirus outbreaks affected in particular known endemic areas in Baden–Württemberg, Bavaria, North Rhine–Westphalia, and Lower Saxony. During the 2010 outbreak, for the first time accumulations of cases were seen in Hesse and Thuringia (23).

Cases of human infection have also been seen in cities, in Cologne, for example, where they were presumed to be due to pathogen exposure in a city park (24).

### Possible causes of the variation in annual case numbers

It is believed that mass reproduction of the bank vole is the cause of the increased occurrence (outbreaks) of disease due to Puumala virus infection. This increase in the population density of rodents is taken to be due to climatic factors and beech mast in the preceding year. Mild and snowy winters probably favor survival of the animals, which then achieve a high population density in the year of the outbreak. The denser the population and the more prevalent the virus in the animal hosts, the more likely it is that transmission to humans as accidental hosts will take place. This therefore suggests a connection between mass reproduction in the bank vole and hantavirus outbreaks in humans. Interestingly, in both winter 2009/spring 2010 and in winter 2011/spring 2012, there was a rise in the number of reported cases very early in the season. Whether such observations can be used as a future early warning system of hantavirus outbreaks remains to be elucidated by further studies.

### Virological diagnosis

Diagnosis of infection in patients is usually by serological procedures such as enzyme immunoassay, immunoblot, or immunofluorescence test (4, 27). Evidence of a de novo hantavirus infection is given by parallel demonstration of IgM and IgG antibodies that react with hantavirus antigen. In routine diagnostics, it is often difficult to distinguish between Puumala and Dobrava–Belgrade virus, either because the antibody demonstration is carried out with antigen of only one of those two viruses, or because serological cross-reactions occur. The hitherto inadequate state of knowledge about the occurrence of Tula virus infections could also be due to the antigenic relationship between Tula virus and Puumala virus. For this reason, the reported virus typing given with case reports passed to the Robert Koch Institute is not very reliable.

A more exact hantavirus typing than the serological methods mentioned above is possible by us of the focus reduction neutralization test (FRNT), in which neutralizing antibodies (directed against the virus envelope) are determined. This method is time-consuming and requires biosafety level 3 laboratory conditions. FRNT is not helpful in finding hitherto unknown types of hantavirus, or for differentiating between infections by the various genotypes of Dobrava–Belgrade virus.

For fine differentiation of viral strains and, for example, mapping them to various different outbreak regions in Germany, viral nucleic acid amplification and sequence analysis is required. This molecular diagnostic procedure is performed on whole blood or serum; however, it is only possible during the first days of symptoms since after that the virus is eliminated from the blood.

### Molecular epidemiological fine differentiation of Puumala virus strains

During the Puumala virus outbreaks in Germany in 2007 and 2010, for the first time viral nucleic acid from a large number of patients was successfully amplified and analyzed (17, 18). In parallel with this, viral genetic material was demonstrated in bank voles in the same...
areas that the patients with proven hantavirus nucleic acid came from. Various outbreak areas were characterized, and Puumala virus nucleotide sequences from patients and from bank voles were analyzed. The viral strains of each outbreak area form their own “molecular cluster,” which is different from that of the neighboring outbreak areas (from [34]: Epidemiologisches Bulletin des Robert Koch-Institutes: Molekulare Unterscheidbarkeit der zirkulierenden Hantavirus-Stämme in den verschiedenen Ausbruchsregionen Deutschlands. Epidem Bull 2012, Nr. 25, 228–31; reproduced by kind permission of the Robert Koch Institute).

**Vertical transmission**

As the number of hantavirus infections rises, the risk increases that pregnant women will become infected with this virus. Despite this, to date there are very few reports of cases where sensitive methods were used to monitor for infection of the child. The largest European study so far reported two pregnant women with acute Puumala virus infection and two others with acute Dobrava–Belgrade virus infection (28). Despite the fact that all four women became ill, in no case did the maternal infection lead to intrauterine damage or infection of the child (observation period up to 12 months after birth).

**Treatment and prevention**

For hantavirus infection, according to § 7 of the German Law on the Prevention and Control of Infectious Diseases, all laboratories have a statutory duty to notify the Ministry of Health when they identify a case of infection associated with acute illness.
Treatment of the disease is symptomatic, with the focus on maintaining cardiovascular stability and compensating temporary organ failure (dialysis, oxygenation). No causative antiviral treatment option exists; results of studies using the virostatic ribavirin are unclear. The same is true of the first, limited attempts to use antiviral cytokines (interferon type I) or immunomodulatory substances (4, 9).

There is no approved vaccine for active immunization against the human pathogenic hantaviruses that are circulating in Europe (4). Genetically engineered vaccines that exist at the laboratory stage have so far not been adopted into development programs by the pharmaceutical industry. For this reason, the main focus of attempts to protect humans from infection is prevention of exposure, i.e., preventing transmission of the pathogen from animal to human. Hantavirus infections could be largely prevented if contact with the voles and their secretions could be prevented (29). This involves controlling the voles in and around human dwellings. When working in places where voles may have been (e.g., when cleaning out stables, sheds, or summer houses at the end of the winter), especially in endemic areas, single-use gloves and masks that fit closely over nose and mouth (e.g., the FFP3 respiratory masks available from DIY stores) should be worn. When out of doors, contact with vole nests and secretions should likewise be avoided. Other measures are to keep food safely both indoors and out of doors, and to disinfect and appropriately dispose of any trapped or dead voles. Since the infection can be transmitted by rodents kept in the laboratory, such as brown rats, common voles and bank voles, these animals too should be regularly examined for any persistent hantavirus infection—even though at present this is only prescribed for brown rats by the Federation of European Laboratory Animal Science Associations (FELASA).

Future perspectives

In the future, renewed efforts must be made to develop virostatics and a vaccine for use in Europe. In the short term, however, preventive measures aimed at reducing exposure of people living in the endemic areas to the pathogen will be the most important. This requires a strengthening of public awareness of this infectious disease. In addition, targeted training courses are needed for hospital physicians and those in private practice—especially in endemic areas—to familiarize them with the symptoms of the disease. The improved understanding of the (immune) pathogenesis underlying hantavirus disease could lead to novel therapeutic pathways. One task to be performed is molecular epidemiological mapping of the outbreak areas at the finest resolution possible and—connected with this—to determine precisely the place where patients were infected, by molecular analyses of viral samples. Further research into the ecological causes of viral outbreaks might in the future be used in the development of an “early warning system.”

Conflict of interest statement

Professor Krüger has received lecture fees from Synlab.
Dr. Hofmann has received lecture fees from Abbott and Siemens.
Dr. Ulrich declares that no conflict of interest exists.

Manuscript received on 19 December 2012, revised version accepted on 18 April 2013.

Translated from the original German by Kersti Wagstaff, MA.

REFERENCES


Translated from the original German by Kersti Wagstaff, MA.

REFERENCES


KEY MESSAGES

- Hantavirus diseases are zoonoses; the pathogens are transmitted from small mammals (rodents) to humans.
- The disease starts with a high fever; depending on severity, shock and renal and/or pulmonary failure may occur.
- The special viral diagnostic procedure relies on serological and molecular biological tests, the last of which enable exact mapping of the hantavirus outbreak areas.
- Given the lack of an approved vaccine, infection prophylaxis consists of avoiding contact with rodents and their secretions.
- In 2012, the number of cases of hantavirus disease in Germany reached a new high at more than 2800 recorded cases.


